Mainz Biomed (NASDAQ:MYNZ – Free Report) had its price target cut by HC Wainwright from $5.00 to $3.00 in a research report report published on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Mainz Biomed’s Q4 2024 earnings at ($0.18) EPS and FY2024 earnings […]